Kiora and Théa Open Innovation Enter Partnership to Develop and Commercialize KIO-301


We are a clinical-stage pharmaceutical company developing and commercializing products for treating ophthalmic diseases.

Kiora Pharmaceuticals is an ophthalmic-focused biotech company with multiple active, clinical stage programs.

Whilst the ophthalmology research community is incredibly innovative and has brought many new therapies to the market over the past few years, there remain multiple unmet needs for patients with ophthalmic diseases. Our goal is to address some of these with our portfolio of promising and exciting therapeutic candidates.

As described further in our Products pages, Kiora is developing KIO-101 for Dry Eye Disease, KIO-201 for Ocular Wound Healing and KIO-301 for inherited and age-related retinal degenerative diseases, including Retinitis Pigmentosa.

Upcoming Events

H.C. Wainwright BIOCONNECT Virtual Conference

January 10 – 13, 2022
Kiora Pharmaceuticals, Inc.
Company Presentation
View the Presentation

Loading RSS Feed